by Alex Kadhim
Researchers from the Hackensack University Medical Center have demonstrated that EZH2, a chromatin-modifying epigenetic enzyme, promotes alloreactive T cell survival during graft-versus-host...
by Alex Kadhim
In a single-center phase 2 study (CAR-PRISM; NCT05767359), researchers from the Dana Farber Cancer Institute have shown that a single infusion of BCMA-directed CAR T cell therapy with...
by Alex Kadhim
Researchers at Bambino Gesù Children’s Hospital in Rome have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed or refractory acute myeloid leukemia, and that...
by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center and City of Hope, together with a multicenter U.S. team and Poseida Therapeutics, have reported early clinical activity for a...
by Alex Kadhim
Researchers at Imperial College London and the University of Oxford have found a bispecific CD19 and CD133 chimeric antigen receptor (CAR) engineered into invariant natural killer T cells can...
by Alex Khadhim
Researchers at Friedrich-Alexander-Universität Erlangen–Nürnberg and Universitätsklinikum Erlangen have found that autologous CD19 CAR T cell therapy can induce rapid, drug-free clinical...